Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1997-2-6
pubmed:abstractText
The aim of this work was to examine the mechanism involved in intestinal elimination of the two optical isomers of ofloxacin in the rat. An intestinal segment was isolated in situ and perfused with saline, while drug solution was administered via the carotid artery. Blood samples and intestinal effluents were collected and analyzed by a high-performance liquid chromatography method. We observed saturable and stereoselective intestinal elimination of the ofloxacin enantiomers. The elimination process favored the R-(+) form of the molecule. After a parenteral dose of 20 mg of racemic ofloxacin per kg of body weight, intestinal clearances were 0.23 +/- 0.03 versus 0.30 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively. Ciprofloxacin and pefloxacin interfered with ofloxacin elimination and significantly reduced the intestinal clearance of S-(-)- and R-(+)-ofloxacin. With concomitant ciprofloxacin, intestinal clearances became 0.13 +/- 0.02 versus 0.17 +/- 0.03 ml/min and 0.14 +/- 0.01 versus 0.19 +/- 0.05 ml/min with pefloxacin for S-(-)- and R-(+)-ofloxacin, respectively. Those findings argue for the presence of a common transport system in the rat intestine with variable affinities for fluoroquinolones. In addition, verapamil and quinidine, two P-glycoprotein blockers, significantly reduced the intestinal elimination of both ofloxacin isomers (with concomitant verapamil, intestinal clearances were 0.12 +/- 0.02 versus 0.18 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively, while with concomitant quinidine, values were 0.18 +/- 0.01 versus 0.23 +/- 0.01 ml/min without modifying their areas under the concentration-time curve in serum. Similar results were found with another fluoroquinolone, ciprofloxacin, in previous work. P-glycoprotein appears to be involved in the intestinal elimination of fluoroquinolones in rats. The characterization of fluoroquinolone intestinal elimination has significant clinical relevance for the better evaluation of the influence of this secretory pathway on antibiotic efficacy and selection of resistant bacteria within the intestinal flora.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-1319875, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-1348245, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-13539795, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-1489194, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-1759834, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2009097, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2009884, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2174762, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2217530, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2222473, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2444983, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2471060, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2501940, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2589388, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-2858094, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3013628, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3159733, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3243831, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3479046, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3481323, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3521490, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3679621, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-3970478, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-6219615, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-7264883, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-7695338, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-7815283, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-7882634, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-8182517, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-8277187, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-8394795, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878593-8467353
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2126-30
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.
pubmed:affiliation
Service de Pharmacie Clinique, Centre Hospitalier Universitaire Bicha-Claude Bernard, Paris, France.
pubmed:publicationType
Journal Article, In Vitro